Presentation is loading. Please wait.

Presentation is loading. Please wait.

Immunohistochemistry staining of interferon (IFN)-λ in renal tissue.

Published bySvein Henriksen Modified over 5 years ago

Similar presentations

Presentation on theme: "Immunohistochemistry staining of interferon (IFN)-λ in renal tissue."— Presentation transcript:

1 Immunohistochemistry staining of interferon (IFN)-λ in renal tissue.
Immunohistochemistry staining of interferon (IFN)-λ in renal tissue. The figure demonstrates a kidney biopsy from a patient with lupus nephritis class IV. The representative micrograph displays IFNλ staining predominantly found in tubular cells and in an incipient cellular crescent in the glomeruli. In the glomeruli without crescent, the staining is sparse. Original magnifications: ×20. Agneta Zickert et al. Lupus Sci Med 2016;3:e000170 ©2016 by Lupus Foundation of America

Download ppt "Immunohistochemistry staining of interferon (IFN)-λ in renal tissue."

Similar presentations

Ann Intern Med. 2015;162(1): doi: /M Figure Legend:

Ann Intern Med. 2015;162(1): doi: /M Figure Legend:
Volume 79, Issue 11, Pages (June 2011)

Volume 79, Issue 11, Pages (June 2011)
Anifrolumab inhibits cytokine production, plasmacytoid dendritic cell (pDC) activation and the type I (interferon gene signature) IFN gene signature. Anifrolumab.

Anifrolumab inhibits cytokine production, plasmacytoid dendritic cell (pDC) activation and the type I (interferon gene signature) IFN gene signature. Anifrolumab.
Figure 1 Pathological features of lupus nephritis subtypes

Figure 1 Pathological features of lupus nephritis subtypes
Histomorphology in a case of mixed (cellular and humoral) acute kidney allograft rejection (patient 10). Histomorphology in a case of mixed (cellular and.

Histomorphology in a case of mixed (cellular and humoral) acute kidney allograft rejection (patient 10). Histomorphology in a case of mixed (cellular and.
Anifrolumab inhibits type I interferon (IFN)-induced IFN-stimulated response element (ISRE) signalling. Anifrolumab inhibits type I interferon (IFN)-induced.

Anifrolumab inhibits type I interferon (IFN)-induced IFN-stimulated response element (ISRE) signalling. Anifrolumab inhibits type I interferon (IFN)-induced.
Time between systemic lupus erythematosus (SLE) and haematological malignancy diagnoses. Time between systemic lupus erythematosus (SLE) and haematological.

Time between systemic lupus erythematosus (SLE) and haematological malignancy diagnoses. Time between systemic lupus erythematosus (SLE) and haematological.
Histologic classification of glomerular diseases: clinicopathologic correlations, limitations exposed by validation studies, and suggestions for modification 

Histologic classification of glomerular diseases: clinicopathologic correlations, limitations exposed by validation studies, and suggestions for modification 
Agnes B. Fogo, MD, Mark A. Lusco, MD, Behzad Najafian, MD, Charles E

Agnes B. Fogo, MD, Mark A. Lusco, MD, Behzad Najafian, MD, Charles E
Quiz Page February 2016 American Journal of Kidney Diseases

Quiz Page February 2016 American Journal of Kidney Diseases
Quiz Page December 2007 American Journal of Kidney Diseases

Quiz Page December 2007 American Journal of Kidney Diseases
Time course for laboratory parameters of a patient with systemic lupus erythematosus prior and during bortezomib therapy (arrow). Time course for laboratory.

Time course for laboratory parameters of a patient with systemic lupus erythematosus prior and during bortezomib therapy (arrow). Time course for laboratory.
Jia-Jung Lee, MD, Hung-Chun Chen, MD, PhD 

Jia-Jung Lee, MD, Hung-Chun Chen, MD, PhD 
C.-W. Tsai, V.-C. Wu, W.-C. Lin, J.-W. Huang, M.-S. Wu

C.-W. Tsai, V.-C. Wu, W.-C. Lin, J.-W. Huang, M.-S. Wu
Volume 77, Issue 9, Pages (May 2010)

Volume 77, Issue 9, Pages (May 2010)
The clinical spectrum of tubulointerstitial nephritis

The clinical spectrum of tubulointerstitial nephritis
Quiz Page December 2008 American Journal of Kidney Diseases

Quiz Page December 2008 American Journal of Kidney Diseases
Volume 75, Issue 12, Pages (June 2009)

Volume 75, Issue 12, Pages (June 2009)
Lupus Nephritis: Mesangial and Membranous Forms (WHO II and V)

Lupus Nephritis: Mesangial and Membranous Forms (WHO II and V)
Mean Safety of Estrogens in Lupus Erythematosus National Assessment–Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score at the last.

Mean Safety of Estrogens in Lupus Erythematosus National Assessment–Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score at the last.

Similar presentations

Ads by Google